{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:10Z","timestamp":1786119430331,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants, and preterm infants are at higher risk of severe illness. While RSV immunoprophylaxis is widely considered necessary for very preterm infants in most countries, its efficacy in moderate-to-late preterm infants (MLPI) remains controversial. This study aimed to evaluate the preventive and therapeutic effects of palivizumab in MLPI, using data from the National Health Insurance Service of Korea. We analyzed the National Health Insurance Service data for infants born during the RSV season (October\u2013March) from 2018 to 2022. Infants with a gestational age of 32 weeks 0 days\u2019 to 36 weeks 6 days\u2019 gestation were categorized as MLPI and those born between 37 weeks 0 days\u2019 and 41 weeks 6 days\u2019 gestation as full-term infants. Infants with congenital anomalies or severe cardiac diseases were excluded. Both groups were divided according to palivizumab administration. We compared the RSV infection rates and hospitalization duration. Of the 593,419 infants, 137,452 were excluded. Among 440,163 full-term infants, 938 (0.23%) received palivizumab, compared with 2096 (13.26%) of 15,804 MLPI. In full-term infants, RSV infection occurred in 0.68% of the non-recipients and 0.21% of the recipients. Among the MLPI, the infection rates were 1.18% in non-recipients and 0.62% in recipients, indicating a statistically significant reduction. Logistic regression analysis revealed that palivizumab reduced the risk of RSV infection in MLPI by an approximately 53% lower odds (adjusted odds ratio, 0.47;\n                      <jats:italic toggle=\"yes\">P\u2005=\u2005<\/jats:italic>\n                      .011). Palivizumab significantly reduced the incidence and severity of RSV infection in MLPI in Korea. This study provides crucial nationwide baseline data on the RSV disease burden in this vulnerable population immediately before the introduction of novel prophylactic strategies such as nirsevimab, and can serve as evidence for future health policy decisions and cost-effectiveness analyses.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048498","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:04:15Z","timestamp":1777273455000},"page":"e48498","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Palivizumab prophylaxis and risk of RSV infection among moderate-to-late preterm infants: A nationwide Korean cohort study from 2018 to 2022"],"prefix":"10.1097","volume":"105","author":[{"given":"Hyejin","family":"So","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"},{"name":"Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghyuk","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Wonju Severance Christian Hospital, Wonju, Gangwon-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngmi","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbyul","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Statistics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoowon","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"},{"name":"Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeesu","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"},{"name":"Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minji","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"},{"name":"Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Hee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"},{"name":"Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geena","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"},{"name":"Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-mi","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"},{"name":"Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5435-606X","authenticated-orcid":false,"given":"Byoungkook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"},{"name":"Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40121-017-0151-4","article-title":"The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood.","volume":"6","author":"Fauroux","year":"2017","journal-title":"Infect Dis Ther"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41372-020-0689-y","article-title":"Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.","volume":"40","author":"Krilov","year":"2020","journal-title":"J Perinatol"},{"key":"R4-20260622","first-page":"55","article-title":"Respiratory syncytial virus and premature infants born at 32 weeks\u2019 gestation or earlier: hospitalization and economic implications of prophylaxis.","volume":"154","author":"Stevens","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(24)00138-7","article-title":"Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.","volume":"403","author":"Wang","year":"2024","journal-title":"Lancet"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"210110","DOI":"10.1183\/20734735.0110-2021","article-title":"Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?","volume":"17","author":"Quinn","year":"2021","journal-title":"Breathe (Sheff)"},{"key":"R7-20260622","first-page":"867","article-title":"AAP issues updated guidance on palivizumab prophylaxis for RSV infection.","volume":"90","author":"Lambert","year":"2014","journal-title":"Am Fam Physician"},{"key":"R8-20260622","doi-asserted-by":"crossref","first-page":"e20160627","DOI":"10.1542\/peds.2016-0627","article-title":"Observed effectiveness of palivizumab for 29-36-week gestation infants.","volume":"138","author":"Farber","year":"2016","journal-title":"Pediatrics"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/pch\/20.6.321","article-title":"Preventing hospitalizations for respiratory syncytial virus infection.","volume":"20","author":"Robinson","year":"2015","journal-title":"Paediatr Child Health"},{"key":"R10-20260622","doi-asserted-by":"crossref","first-page":"56","DOI":"10.14745\/ccdr.v46i04a01","article-title":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada.","volume":"46","author":"Killikelly","year":"2020","journal-title":"Can Commun Dis Rep"},{"key":"R11-20260622","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.3346\/jkms.2024.39.e279","article-title":"Impact of palivizumab in preventing severe acute lower respiratory infection in moderate-to-late preterm infants: a nationwide cohort study.","volume":"39","author":"Kim","year":"2024","journal-title":"J Korean Med Sci"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000528914","article-title":"European consensus guidelines on the management of respiratory distress syndrome: 2022 update.","volume":"120","author":"Sweet","year":"2023","journal-title":"Neonatology"},{"key":"R15-20260622","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jpeds.2018.01.043","article-title":"Bronchopulmonary dysplasia: executive summary of a workshop.","volume":"197","author":"Higgins","year":"2018","journal-title":"J Pediatr"},{"key":"R16-20260622","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/uog.15884","article-title":"Consensus definition of fetal growth restriction: a Delphi procedure.","volume":"48","author":"Gordijn","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"Suppl 1","key":"R17-20260622","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/infdis\/jiac059","article-title":"A systematic review of European clinical practice guidelines for respiratory syncytial virus prophylaxis.","volume":"226","author":"Reeves","year":"2022","journal-title":"J Infect Dis"},{"key":"R18-20260622","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children.","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"R19-20260622","doi-asserted-by":"crossref","first-page":"e2023061803","DOI":"10.1542\/peds.2023-061803","article-title":"Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.","volume":"152","author":"Caserta","year":"2023","journal-title":"Pediatrics"},{"key":"R20-20260622","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamapediatrics.2013.2636","article-title":"Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.","volume":"167","author":"Winterstein","year":"2013","journal-title":"JAMA Pediatr"},{"key":"R21-20260622","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.aller.2014.06.006","article-title":"Hospital admission due to respiratory viral infections in moderate preterm, late preterm and term infants during their first year of life.","volume":"43","author":"Olabarrieta","year":"2015","journal-title":"Allergol Immunopathol (Madr)"},{"key":"R22-20260622","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/INF.0000000000001377","article-title":"Burden of severe respiratory syncytial virus disease among 33-35 weeks\u2019 gestational age infants born during multiple respiratory syncytial virus seasons.","volume":"36","author":"Anderson","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20260622","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"R24-20260622","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0039-1681014","article-title":"SENTINEL1: two-season study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks\u2019 gestational age not receiving immunoprophylaxis.","volume":"37","author":"Anderson","year":"2020","journal-title":"Am J Perinatol"},{"key":"R25-20260622","first-page":"43","article-title":"Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the Impact-RSV trial by gestational age group.","volume":"5","author":"Notario","year":"2014","journal-title":"Pediatr Health Med Ther"},{"key":"R26-20260622","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1874285801105010144","article-title":"Risk factors for severe respiratory syncytial virus lower respiratory tract infection.","volume":"5","author":"Sommer","year":"2011","journal-title":"Open Microbiol J"},{"key":"R27-20260622","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-virology-091919-092720","article-title":"Sex differences in respiratory viral pathogenesis and treatments.","volume":"8","author":"Ursin","year":"2021","journal-title":"Annu Rev Virol"},{"key":"R28-20260622","doi-asserted-by":"crossref","first-page":"23741","DOI":"10.1038\/s41598-021-03044-x","article-title":"Sex differences in innate anti-viral immune responses to respiratory viruses and in their clinical outcomes in a birth cohort study.","volume":"11","author":"Regis","year":"2021","journal-title":"Sci Rep"},{"key":"R29-20260622","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3855\/jidc.12561","article-title":"Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.","volume":"15","author":"Pi\u00f1eros","year":"2021","journal-title":"J Infect Dev Ctries"},{"key":"R30-20260622","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S2213-2600(20)30322-2","article-title":"National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study.","volume":"9","author":"Li","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R31-20260622","doi-asserted-by":"crossref","first-page":"e046563","DOI":"10.1136\/bmjopen-2020-046563","article-title":"Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.","volume":"11","author":"Baral","year":"2021","journal-title":"BMJ Open"},{"key":"R32-20260622","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/cid\/ciae596","article-title":"Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: analysis from a phase 3 randomized clinical trial (MELODY).","volume":"81","author":"Arbetter","year":"2025","journal-title":"Clin Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:28Z","timestamp":1786039708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":30,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048498","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2025-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}